Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
about
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsRefined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Managing patients with myelofibrosis and low platelet counts.Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaRadionuclide imaging of bone marrow disorders.Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Prognosis of Primary Myelofibrosis in the Genomic EraPrimary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.Leukemic transformation in essential thrombocythemia.Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.Prognostication in primary myelofibrosis.PREDICT: a diagnostic accuracy study of a tool for predicting mortality within one year: who should have an advance healthcare directive?Developmental Therapeutics in Myeloproliferative Neoplasms.Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.SOHO State-of-the-Art Update and Next Questions: MPN.Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.Expression of CD markers in JAK2 positive myeloproliferative neoplasms: Prognostic significance
P2860
Q26786893-D274ECE8-1EFB-4B7F-BDAD-DFD60D34C779Q33392291-8BD4F239-4016-4FF5-9A42-3EC5EC402648Q33393151-63D83573-DFB8-4051-BE49-50D8ED1E0D14Q33406990-3C3F9846-0409-4B32-8E67-970F50077FF3Q33430113-C8CD5EF0-CE39-41C2-9278-49CFD4950849Q33432406-4A37B816-72C3-442B-8165-FDC3B820C051Q34474214-CFE76E3F-C295-439D-90BA-0F45A78BBE39Q36001930-97322349-57D6-4480-8454-1219A80B7B3FQ37513369-A2CC8218-F17E-4826-9BA6-7A31E05F455AQ37772107-7C05128C-02A3-4FED-A13A-235213C9EF73Q37956603-834A7F43-8FE6-42FA-8CF9-8E10363FE1CEQ38014534-3FD71C13-91CD-469B-861D-546B8BD5DB9BQ38076672-36C6F0A3-1DF6-4763-9EEB-E378B02BD8F9Q38174781-44EF3B38-D508-47DE-80EE-2A5CF7C5152DQ38429716-52F3F2DC-AA66-4676-A793-64A07DFBE9D0Q38567540-F93F7B87-4E04-410E-914D-B6BFE2ABDF4BQ38673830-04EF0D4E-08AC-4B6C-865E-86A2C02BF1DDQ38683077-D05DED75-7B9A-42DB-BF40-2597DA7214E3Q38684435-6C49D63E-0C3D-4992-A439-6D2A15ACD635Q38691019-E48958C8-31B2-4A61-B2B3-5ACF18E12A8CQ38844669-9CC4F496-EF9E-441A-B106-A9B8BB831EE0Q38926804-CBB04BC9-BC79-4DF1-9500-C75E3B488D08Q39015300-1E8CE4B7-88B8-42E2-AD99-1ACCA5C958F3Q39069487-9062A422-1F8C-4F11-9CCA-18E389C962D5Q39255427-B6E5A5AE-A5FF-4D12-BA13-DDBD53E7C4ADQ40497461-FD9768EB-0761-4A3B-98F6-8D2A04797D92Q40560166-2DD951ED-2A22-4774-9C5F-870A192D4D26Q41466915-11CEB137-5DC0-4388-A1B7-EE6D95AE7AC8Q42385052-B4FD0AD4-B1C3-4318-AD94-E382A154427AQ44731549-F4AFD870-97DD-4277-9FDA-6503391F9C00Q45164196-CF94504A-DD2A-4118-8C67-86AEF04FEE5CQ48008083-BE536ECD-A914-437A-8F31-9E2A19BB06A4Q48144615-5C24988F-01AF-43E2-BEF7-3DF591679ED1Q49580473-D9AAD2A4-61B1-4A67-B80D-E889A3743B42Q50462637-0C6185B7-F90A-49F7-A25B-6DAC5BD5E4B8Q51270030-6AF04F8F-B48E-4559-9566-96045927CF90Q53136705-8F12B374-99A5-4BD1-8378-3D90486B9FBBQ58587352-E03483F4-1817-4330-A672-9910AAE8E5A9
P2860
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@en
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@nl
type
label
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@en
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@nl
prefLabel
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@en
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@nl
P2093
P2860
P50
P356
P1476
Dynamic model for predicting d ...... thrombocythemia myelofibrosis.
@en
P2093
Alice Lynn
Constantine S Tam
Deborah A Thomas
Lingsha Zhou
P2860
P304
P356
10.1200/JCO.2009.22.8833
P407
P577
2009-09-28T00:00:00Z